Cornerstone Therapeutics (CRTX) 8-K Cornerstone Therapeutics Announces Management Change

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 1, 2009

Cornerstone Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation) 000-50767
(Commission
File Number) 04-3523569
(IRS Employer
Identification No.)

1255 Crescent Green Drive, Suite 250, Cary, NC
(Address of Principal Executive Offices) 27518
(Zip Code)

Registrant’s telephone number, including area code:(919) 678-6611

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Ex-99.1 Press Release dated April 7, 2009

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     On April 1, 2009, Cornerstone Therapeutics Inc. (the “Company”) was notified by Chenyqua M. Baldwin, the Company’s Vice President, Finance, Chief Accounting Officer and Controller, that she intends to leave the Company on or about May 6, 2009 to pursue other opportunities.

     A copy of the Company’s press release announcing Ms. Baldwin’s resignation from the Company is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

     See the Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CORNERSTONE THERAPEUTICS INC.
Date: April 7, 2009	By:	/s/ Craig A. Collard
		Craig A. Collard
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description of Document
Exhibit 99.1	Press Release of Cornerstone Therapeutics Inc. dated April 7, 2009.